Related Experiment Videos
Apathy and executive function in Alzheimer's disease.
Susan McPherson1, Lynn Fairbanks, Sibel Tiken
1Alzheimer's Disease Center, Department of Neurology, UCLA School of Medicine, Los Angeles, California 90095-1769, USA. susanmcp@ucla.edu
Summary
Apathy in Alzheimer's disease (AD) is linked to executive dysfunction, not dysphoria. Cognitive tests accurately identified apathy in 75% of AD patients, highlighting executive function
Area of Science:
- Neuropsychology
- Neurology
- Geriatric Medicine
Background:
- Apathy is a frequent behavioral symptom in Alzheimer's disease (AD).
- Previous research suggests apathy in AD may relate to frontal lobe dysfunction.
- Standardized neuropsychological assessments are underutilized in exploring this relationship.
Purpose of the Study:
- To investigate the association between apathy and executive dysfunction in Alzheimer's disease patients.
- To determine if apathy is linked to specific neuropsychological deficits.
- To differentiate apathy from dysphoria in the context of cognitive function.
Main Methods:
- Administered a comprehensive neuropsychological test battery and behavior rating scale to 80 AD patients.
- Assessed executive functions using tests like WAIS-R Digit Symbol, Trail-Making, and Stroop Color Interference Test.
- Examined the relationship between executive function performance, apathy, and dysphoria.
Main Results:
- AD patients with apathy exhibited significantly poorer performance on executive function tests compared to those without apathy.
- Executive function measures collectively achieved 75% accuracy in classifying patients as apathetic or nonapathetic.
- No significant relationship was found between executive functions and dysphoria; apathy was distinct from dysphoria.
Conclusions:
- Apathy in Alzheimer's disease is strongly associated with executive dysfunction.
- Neuropsychological deficits unrelated to executive functions do not correlate with apathy.
- Apathy represents a distinct clinical entity separate from dysphoria in AD.